MDV3100 gets a proper scientific name - New Prostate Cancer Infolink

Posted on April 4, 2012 by Sitemaster

According to a media release issued by Medivation immediately prior to the annual meeting of the American Associatiuon for Cancer Research in Chicago (now wrapping up), the drug we have all known as MDV3100 for the past few years now has an approved ?scientific? name: enzalutamide.

This nomenclature clearly indicates that MDV3100 is a form of antiandrogen, like other drugs whose names end in ?-utamide? (e.g., flutamide, bicalutamide, nilutamide). On the other hand, it is apparent from the clinical efficacy data that enzalutamide appears to work in men who are non-responsive to the older ?-utamides?.

Perhaps one simple way to think about this is that if flutamide was the original, ?first generation? -utamide antiandrogen, and bicalutamide (Casodex) was the only member of the ?second generation? of these products, then arguably enzalutamide is the first (and to date the only) member of a ?third generation? of this class of agents.

We still have no idea what the ?brand? name of enzalutamide is going to be, i.e., the name that that is to enzalutamide what Zytiga is to abiraterone acetate.

Like this:

Be the first to like this post.

Filed under: Drugs in development Tagged: | antiandrogen, enzalutamide, MDV3100

norman reedus sears office max office max cyber monday deals 2011 cyber monday deals 2011 real housewives of atlanta